

Original Research

Sex-Associated Radiographic and Clinical Differences in Nontuberculous Mycobacteria Pulmonary Disease

Bryan Garcia, MD^{1*} Matthew Mullins, BSc^{2*} Lindsay Lim, MD, DTMH³ German Henostroza, MD³ Camilla Margaroli, PhD⁴

¹ Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States

² University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States

³ Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, United States

⁴ Division of Molecular and Cellular Pathology, Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, United States

* *co-first authors*

Address correspondence to:

Camilla Margaroli, PhD
Division of Molecular and Cellular Pathology
Department of Pathology
University of Alabama at Birmingham
901 19th St S, Birmingham, AL 35205
Phone: (205) 975-1077
Email: cmargaroli@uabmc.edu

Running Head: Sex-Associated Differences in NTM Infection

Key words: nontuberculous mycobacterial lung infections; lung disease; gender bias

Abbreviations: BMI = body mass index; CF = cystic fibrosis; COPD = chronic obstructive pulmonary disease; CT = computed tomography; FEV₁ = Forced Expiratory Volume in 1 minute; GERD = Gastroesophageal reflux disease; ILD = Interstitial Lung Disease; MAC = *Mycobacterium avium complex*; NTM = nontuberculous mycobacteria; NTM-PD = NTM pulmonary disease; PA/a = pulmonary artery to aorta; SLE = Systemic Lupus Erythematosus

Funding Support: This work was supported by the University of Alabama at Birmingham (UAB) CF Research Center Pilot Grant (CM) under the UAB Research and Development Program from the Cystic Fibrosis Foundation – ROWE19RO (DAVIS).

Date of Acceptance: September 17, 2025 | ***Published online date:*** October 3, 2025

Citation: Garcia B, Mullins M, Lim L, Henostroza G, Margaroli C. Sex-associated radiographic and clinical differences in nontuberculous mycobacteria pulmonary disease. *Chronic Obstr Pulm Dis*. 2025. Published online October 3, 2025.

<https://doi.org/10.15326/jcopdf.2025.0622>

Abstract

The incidence of infections caused by nontuberculous mycobacteria (NTM) are steadily increasing worldwide and the most common site of infection is the lung. Clinical characteristics of individuals with NTM pulmonary disease (NTM-PD) demonstrate pronounced geographical heterogeneity. In the United States, NTM-PD has an affinity for post-menopausal Caucasian females, many of whom are never-smokers, whereas in Asia NTM-PD is more common in males with post-tuberculosis lung disease. While these geographical differences are known on the global scale, it remains unclear whether radiographic sex-associated differences in NTM-PD are present within the US cohort. In this single center cross-sectional retrospective study of our patient registry, we sought to assess this knowledge gap by comparing radiographic and clinical features of individuals with NTM-PD by sex. We observed a significant preponderance of cavitary disease in men, while women commonly presented with bilateral apical fibrosis, increased nodules and tree-in-bud patterns in the lower lobes, and an increased risk of refractory disease and concomitant co-infection. Results from this study demonstrate several sex-associated differences in the radiographic phenotype of NTM-PD, and may be the result of differences in pre-existing risk factors that contribute to the development of NTM-PD. Future studies will be required to better assess the broad applicability of these findings to centers from other geographic regions where the underlying etiology of disease may vary.

Introduction

Nontuberculous mycobacteria (NTM) are environmentally ubiquitous organisms, commonly isolated from water and soil environments, and have become a global healthcare challenge with the frequency and incidence of NTM infections steadily increasing worldwide¹. In the United States, NTM incidence increased from 1 to 2 cases per 100,000 individuals in the 1980s, to 47 cases per 100,000 in 2007^{2,3}. Similar trends have been observed in Europe, Asia, and Australia^{1,4}. The increased incidence of NTM infections is attributed to several factors including HIV, increased use of iatrogenic immunosuppression, an aging cohort that encompasses a larger component of the general population, increased recognition on chest imaging, and improved culture methodology. Interestingly, regional differences in NTM patient demographics are apparent. For example, in eastern Asia, the majority of patients with NTM-PD are males (79%) with 37% of them presenting with post tuberculosis lung disease⁵, whereas in the US, NTM-PD has been associated with post-menopausal Caucasian females with slender build and skeletal abnormalities including scoliosis and pectus excavatum. Many of these individuals have no pre-existing immunodeficiency or smoking history and this disease phenotype has been termed “Lady Windemere syndrome”⁶.

NTM pulmonary infections can be caused by different mycobacteria. Infections worldwide are predominantly caused by *Mycobacterium avium* complex (MAC) (47% of total infections worldwide⁷), however geographical differences are present even within the same continent. In eastern Asia, MAC is most commonly isolated in Japan, India, Taiwan, Singapore, Thailand, and South Korea, while in China and Hong Kong *M. chelonae* and *M. goodii* are the predominant NTM species isolated⁵. In the US, regional geographic variances have also been observed, which

could be, at least in part, attributed to the variety of environmental conditions in the US. As an example, although MAC is the most commonly identified species causing NTM-PD in the US, *M. abscessus* subspecies is responsible for as much as 31.8% of NTM-PD in the state of Florida highlighting the heterogeneity of this disease within the same country ¹.

The heterogeneity of disease severity caused by NTM infections is not fully explained by etiology or microbiology alone. As an example, approximately 45% percent of patients with NTM isolated from the airway will not initially require treatment at the time of first isolation and guidelines for which individuals should be treated exist ⁸⁻¹². In addition to disease heterogeneity, striking differences in treatment efficacy and disease course are present in this patient population, with some individuals presenting with MAC infection achieving a sustained culture conversion following 18 months of oral antibiotics, while others will suffer from chronic recalcitrant infections requiring a combination of oral, inhaled, and intravenous antibiotics for life ¹³.

A variety of pre-existing risk factors for the acquisition of NTM species and the development of subsequent pulmonary disease have been described. In the case of individuals with cystic fibrosis (CF) and Primary Ciliary Dyskinesia, monogenetic mutations have been identified and are critically important risk factors in the development of NTM infections. However, only a small subset of individuals suffering from CF or PCD will go on to acquire NTM infections ^{14,15} suggesting that for these individuals additional risk factors exist and may include environmental exposures, pre-existing lung disease severity, age, and sex. Most individuals with NTM-PD in the US however do not have a monogenetic disease that provides an explanation for the development of NTM-PD and according to the American Lung Association more than 86,000 individuals are estimated to have NTM-PD in the US. For these individuals a broad spectrum of risk factors have

been identified and include chronic immunosuppression and underlying structural lung remodeling due to non-CF bronchiectasis, gastroesophageal reflux disease (GERD), prior tobacco abuse and chronic obstructive pulmonary disease (COPD) ^{16,17}. However, while COPD is a common comorbidity in NTM-PD, association of smoking with NTM infection remains unclear, and similarly only a small subset of current and former smokers will go on to acquire NTM infections of the lung.

Previous studies have sought to radiographically phenotype cohorts of NTM-PD patients ¹⁸⁻²⁰ and a formal staging or scoring system for NTM-PD severity using chest imaging does not currently exist. At present, NTM-PD is generally described radiographically as either “nodular-bronchiectatic” or “cavitary” ²¹⁻²⁴. In a systematic review, NTM-PD was shown to have a five-year rate of mortality of 27% in Europe, 35% in the US, and 33% in Asia, with male sex, presence of comorbidities, and fibro-cavitary disease predicting high mortality ²⁵. Further, culture conversion rates in NTM-PD tend to be higher in the nodular-bronchiectatic disease compared to the fibro-cavitary form ^{12,26,27}. Nevertheless, these studies have yet to assess radiographic sex-based differences in NTM-PD, which given the female sex predisposition in the USA towards acquiring this infection may provide insight into the differing risk factors and disease severity seen across sexes. This knowledge gap prevents a clearer understanding of the interplay between NTM pulmonary pathophysiology and concomitant pulmonary diseases, which may necessitate additional therapies for some individuals and suggest potential risk factors for the acquisition of NTM infections. Here, we report a single center cross-sectional retrospective study of our patient registry highlighting radiographic differences by sex amongst people affected by NTM-PD. These results build upon the pre-existing literature towards a broader understanding of sex differences in radiographic findings on NTM-PD globally.

Methods

Clinical data were obtained retrospectively (The University of Alabama, Bronchiectasis Research Registry, IRB Project Number (IPN): IRB-300010437) for patients seen at a large academic NTM care center in the south eastern USA. Patients with CF were excluded from this retrospective collection. Data was collected in October 2024 for 191 patients, 10 were excluded as they presented with skin and soft tissue infection and 181 were identified as having pulmonary infection and were used in the analysis. Clinical data included demographics (age, sex, race), body mass index (BMI), smoking history, Percent Predicted Forced Expiratory Volume in 1 minute (FEV_{1pp}), microbiological profiling of sputum and bronchoalveolar lavage, treatment history, evidence of culture conversion or refractory disease, and comorbidities associated with NTM infection (bronchiectasis, GERD, COPD, emphysema, , rheumatologic disease, Interstitial Lung Disease (ILD), lung cancer, other non-lung malignancies), evidence of pectus excavatum, hiatal hernia, or scoliosis.

Chest CT scans were obtained from the most recent visit and were reviewed by a board-certified pulmonologist and an infectious disease specialist who serve as Co-Directors of the NTM care center. The physicians were blinded to patients' clinical outcomes. Assessment of radiographic features was performed by both specialists independently for all 181 CT scans. The chest CT closest in time point to the start of the study period was used for the analysis. All chest CTs were performed for routine clinical purposes and there was not a standardized method for imaging acquisition including variability in slice thickness and some individuals had high resolution CT scans that included inspiratory and expiratory images while others had standard chest CT's performed. The clinicians reviewed chest imaging independent of each other and used

a standardized template to manage data collection. The template separated the lungs by lobe, including a section for the lingula, with each lobe being assessed for the following: bronchiectasis, presence of cavitary lesions, fibrosis, emphysema, tree-in-bud changes, atelectasis, nodules, lobectomy, ground glass opacity, and consolidation. Each lobe was scored using the modified Reiff scoring system²⁸. Imaging data that was obtained was then reviewed in tandem by the clinicians for each individual's chest CT and when differences between clinicians was identified the clinicians re-reviewed that subjects imaging and reached a decision by consensus. NTM-PD (symptomatic) was defined as per the ATS/ISDA criteria¹¹ as presence of disease on CT scan (with or without cavitation), two or more positive sputum cultures or one bronchoalveolar lavage culture for an NTM species, and presence of active significant symptoms attributed to NTM infection. Statistical analysis of sex-associated differences were performed in JMP Pro® v18 (SAS Institute Inc.) using ChiSquare test, Fisher's exact 2-Tail test and Wilcoxon rank sum test as indicated.

Results

Study cohort

A total of 181 patients were identified as having an NTM isolate from the airway were identified (**Table 1**). Of these, 129 individuals (71.3%) were female, and the median age was 71 years. In line with the previously reported features of NTM-PD patients in the US, our cohort was predominantly Caucasian (85.6%) and 77.3% of individuals were infected with MAC. The median FEV_{1pp} was 71%, the median modified Reiff score was 5, and the pulmonary artery to aorta ratio (PA/A ratio) was abnormal in 13 patients (7.1%). Of the 181 patients identified, 146

(80.7%) were diagnosed as having active NTM-PD defined using the ATS/IDSA criteria, of which 41 individuals (22.7%) had radiographic evidence of cavitary disease on their CT scan, and 77 (42.5%) reported a history of smoking.

Comorbidities commonly associated with NTM infection were reported for 122 individuals, with GERD being the most common (38.1%), followed by emphysema (17%), and COPD (17%), and 13.2% of patients were on immunosuppressant therapies for other comorbid conditions. 30.9% of individuals reported two or more comorbid conditions associated with NTM-PD.

NTM infections were predominantly caused by MAC (77.3%) followed by *M. abscessus* (4.4%), while 12 individuals (6.6%) presented with multiple NTM species. Further, co-infections with other microorganisms were present in 32.6% of individuals, with *P. aeruginosa* co-infection being the most common (37.3%). Additionally, 13.6% of individuals had fungal species isolated from the airway, and 11.9% of individuals had polymicrobial co-infections with 2 or more microorganisms detected in addition to NTM.

Regarding treatment regimen, drug sensitivity profiles were available for 82 patients. Of the patients included in this study, 97 (53.6%) patients were on treatment, of which 14 patients were on inhaled antibiotics (7.7%) and 10 patients were actively receiving intravenous antibiotic treatment (5.5%). 13 patients showed resistance to macrolides (13.9%), 49 patients to moxifloxacin (27.1%), 49 patients to linezolid (27.1%), 7 to amikacin (3.8%), and 18 to tetracyclines (9.9%). Further, 50 of the 64 (78.1%) presented with resistance to 2 or more antibiotics, and 62 patients (34.3%) presented with treatment refractory infections defined as persistently positive cultures despite greater than six months of a multi-drug regimen.

Sex differences in NTM pulmonary disease

Male and female patients were demographically similar and did not significantly differ in median age (males 68 years vs. females 71 years), BMI (23.9 kg/m² male vs. 22.4 kg/m² female), number of comorbidities, FEV₁pp, PA/a ratio, Reiff's score, or frequency of symptomatic pulmonary disease (males 78.8% vs. females 81.4%) (**Table 2**). Both cohorts were predominantly Caucasian race (84.6% males, 86% females), however, African Americans represented 13.5% of the male cohort compared to 5.4% in the female group. While the number of comorbidities did not differ between the two cohorts, men were more likely to present with a history of smoking (65.4% male vs. 34.1% female, $p=0.0001$), emphysema (38.5% male vs. 8.53% female, $p<0.0001$), and COPD (30.8% male vs. 11.6% female, $p=0.002$), while women presented more frequently with hiatal hernia although statistical significance was not met (38% female vs 25% male, $p=0.06$).

Although most infections were caused by MAC in both males and females, females had higher rate of infections caused by *M. abscessus* (6.2% vs 0%), while males were more prone to present with multiple and concurrent species of NTM (3.9% vs 13.5%, $p=0.012$) (**Table 3**). Additionally, while no significant difference was observed in how many patients experienced co-infection (36% female and 31.9% male), correspondence analysis of co-infection with other microorganisms showed that fungal infections and polymicrobial infections were more common in females while co-infection with *P. aeruginosa* was more common in males. Interestingly, presence of co-infection in females was significantly associated with refractory NTM infection ($p=0.0003$), while this difference was not observed in the male group.

Lastly, no significant difference was observed in our cohort between male and female in the development of resistance to antibiotics, as female and males showed a frequency of resistance to antibiotics of 35% and 37%, respectively. Likewise, there we found no difference in resistance based on smoking status. However, male patients were more likely to undergo treatment with intravenous antibiotics (13.5% vs 2.33%, $p=0.007$) and to have a treatment regimen with 2 or more concurrent antibiotics (59.6% male vs 42.6% female, $p=0.03$). Further, despite treatment regimen, male patients were less likely to have previously achieved culture conversion compared to female, independent of smoking history, and were more likely to have received treatment durations in excess of one year at the time of data collection (67.3% vs 48.1%, $p=0.003$). This finding remained even in the absence of a history of smoking (66.67% vs 45.78%) (**Table 2**).

Radiographic sex-associated differences in NTM Pulmonary Disease

Radiographic analysis of CT scans demonstrated bronchiectasis in all individuals, however men were more likely to have cavitary disease (38.5% male vs. 16.3% female, $p = 0.001$, **Table 4**). Females with NTM had higher rates of upper lobe predominant fibrotic changes (Right upper lobe: 45.7% female vs. 28.8% male, $p = 0.02$; Left upper lobe: 42.6% female vs. 25% male, $p = 0.03$), tree-in-bud patterns (Right lower lobe: 61.2% female vs. 42.3% male, $p = 0.02$) and nodules (Right lower lobe: 66.7% female vs. 44.2% male, $p = 0.005$) in the lower lobes.

Given the known relationship of exposure to cigarette smoke with chronic inflammation and airway remodeling which can include the development of bronchiectasis, we also investigated

whether history of smoking could be influencing the presence of cavitary disease in both cohorts. Interestingly, males were more likely to experience cavitary disease than females independently of their history of smoking, suggesting that additional mechanisms are potentially participating in the process of tissue remodeling based on sex.

Discussion

Female sex has long been recognized as a risk factor for the development of NTM-PD in the US cohort however sex-associated differences in clinical and radiographic patterns remains poorly understood. Analysis of our patient registry has demonstrated key differences in the radiographic features of individuals with NTM isolated from the airway between sexes. Our study complements and expands upon a previous report of sex-based differences in the development of bronchiectasis in NTM-PD²⁹. Indeed, while the cohort in this study is highly similar to the cohort presented in the study by Ku and colleagues, our results identified key differences in presence of structural lung disease, including cavitary lesions, as well as differences in co-infection and refractory disease. Further, we observed that presence of co-infection in females was significantly associated with refractory NTM infection highlighting the need to better define changes in the airway microbiome related to the structural and microbiological changes related to the underlying lung disease³⁰⁻³², as well as following NTM infection, as it could affect the efficacy of treatment regimens³³.

Likewise, our study shows that nodules were identified in more than 90% of patients in our cohort, highlighting that screening for NTM infection in patients that present with these radiographic features may lead to more rapid diagnosis for patients. Further, several studies in

NTM infection have utilized different scoring systems to quantify lung disease. Here, we selected the modified Reiff's score as a metric for lung disease, as it provides a quantitative assessment of the overall geographic severity of bronchiectasis by lobe and also seeks to quantify the severity of bronchiectasis within each lobe (tubular, varicose, cystic). However, given the heterogeneity in the patient population, underlying lung diseases, other predisposing factors, as well as current unknowns in the etiology and progression of NTM-PD, these factors should be considered when more sensitive scoring systems will be developed for NTM-PD.

Presence of apical fibrosis was remarkably common amongst females with NTM and has not previously been described in association with NTM-PD. These patients did not receive anti-fibrotic therapies, as these changes were felt to be secondary to chronic infection as opposed to an interstitial lung disease although the relationship between this unique finding and NTM infection deserves further evaluation. It has been previously reported that key pathways related to the development of tissue fibrosis are differentially regulated based on sex³⁴, however, whether these differences are at play in NTM-PD is yet to be determined.

Females in our cohort were more prone to present with mid-lower lung disease, an increased incidence of GERD and hiatal hernia compared to men, suggesting that GERD may be a greater contributor to NTM lung infection in women. These high rates of hiatal hernia on chest imaging which have not previously been well described among demographically similar cohorts of individuals infected by NTM suggest aero-digestive disease as a contributing factor to disease acquisition and progression. These findings highlight the importance of clinical assessment for the airway-esophageal interplay and individuals with these findings may benefit from

consultation with gastroenterologists and treatment of concomitant issues due in part by acid reflux.

Further, our study highlights the importance of chest imaging to determine underlying lung disease and inform adjunctive therapies in addition to the standard anti-microbial care.

Lastly, it is important to acknowledge that other factors, such as years of smoke exposure and pack-per-year, could influence outcomes, as well as diagnosis bias due to social constructs.

While the majority of our patients were symptomatic, 54% of patients in the asymptomatic group presented with a history of smoking and none presented with *M.abscessus* infection. In this subset 47% were males, while in the non-smoking asymptomatic group only 12% were males, suggesting different disease etiologies even in asymptomatic patients. Further studies addressing the interplay between host variability, predisposing factors, and hormonal signaling in NTM-PD will be required.

While this study shows significant sex-based differences in this NTM cohort, several limitations are also present. First, this study is a single-center study from the southeast region of the USA. Given the geographical variability of NTM species observed worldwide, it may not have global generalizability, and thus other single-center and multi-center studies will be required to determine its applicability in other US regions and worldwide. Likewise, this cohort was demographically homogenous with high rates of Caucasians in both male/female cohorts limiting the generalizability to international application where higher rates of smoking and post-tuberculosis lung disease, as well as alternative etiologies for the development of NTM lung infections are more prominent. Lastly, images were performed for clinical purposes and there was not a standardized method of imaging acquisition including variability in slice thickness

and with some patients having CT chest while others had high resolution CT with inspiratory and expiratory images thus minor differences may have been noted if all images were obtained using the same modality.

In conclusion, this study highlights key radiological, microbiological, and likely etiological differences between sexes in NTM infection. While these observations may be applicable to other centers across the US presenting with a population with equivalent demographics, as well as areas where the etiology of NTM-PD in men is tied to a history of smoking but not to post-tuberculosis NTM-PD, these key differences warrant consideration in future multicenter studies, overcoming the single-center retrospective limitations of our results, the applicability to other areas where *M. abscessus* may be more prevalent, as well as further assessment of sex-based adjunctive therapies.

Acknowledgments: M.M, L.L. and B.G. collected and compiled the clinical data, C.M. performed the analysis, C.M. and B.G. wrote the manuscript, all authors edited the manuscript for final approval.

Conflict of interest statement: The authors declare no conflict of interest.

References

1. Prevots DR, Marshall JE, Wagner D, Morimoto K. Global Epidemiology of Nontuberculous Mycobacterial Pulmonary Disease: A Review. *Clin Chest Med*. Dec 2023;44(4):675-721. doi:10.1016/j.ccm.2023.08.012
2. Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. *Am J Respir Crit Care Med*. Apr 15 2012;185(8):881-6. doi:10.1164/rccm.201111-2016OC
3. O'Brien RJ, Geiter LJ, Snider DE, Jr. The epidemiology of nontuberculous mycobacterial diseases in the United States. Results from a national survey. *Am Rev Respir Dis*. May 1987;135(5):1007-14. doi:10.1164/arrd.1987.135.5.1007
4. Dahl VN, Molhave M, Floe A, et al. Global trends of pulmonary infections with nontuberculous mycobacteria: a systematic review. *Int J Infect Dis*. Dec 2022;125:120-131. doi:10.1016/j.ijid.2022.10.013
5. Simons S, van Ingen J, Hsueh PR, et al. Nontuberculous mycobacteria in respiratory tract infections, eastern Asia. *Emerg Infect Dis*. Mar 2011;17(3):343-9. doi:10.3201/eid1703.100604
6. Bents SJ, Mercaldo RA, Powell C, Henkle E, Marras TK, Prevots DR. Nontuberculous mycobacterial pulmonary disease (NTM PD) incidence trends in the United States, 2010-2019. *BMC Infect Dis*. Oct 2 2024;24(1):1094. doi:10.1186/s12879-024-09965-y
7. Hoefsloot W, van Ingen J, Andrejak C, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. *Eur Respir J*. Dec 2013;42(6):1604-13. doi:10.1183/09031936.00149212
8. Albelda SM, Kern JA, Marinelli DL, Miller WT. Expanding spectrum of pulmonary disease caused by nontuberculous mycobacteria. *Radiology*. Nov 1985;157(2):289-96. doi:10.1148/radiology.157.2.4048433
9. Levin DL. Radiology of pulmonary Mycobacterium avium-intracellulare complex. *Clin Chest Med*. Sep 2002;23(3):603-12. doi:10.1016/s0272-5231(02)00009-6
10. Miller WT, Jr. Spectrum of pulmonary nontuberculous mycobacterial infection. *Radiology*. May 1994;191(2):343-50. doi:10.1148/radiology.191.2.8153304
11. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med*. Feb 15 2007;175(4):367-416. doi:10.1164/rccm.200604-571ST
12. Moon SM, Jhun BW, Baek SY, et al. Long-term natural history of non-cavitary nodular bronchiectatic nontuberculous mycobacterial pulmonary disease. *Respir Med*. May 2019;151:1-7. doi:10.1016/j.rmed.2019.03.014
13. Flume PA, Griffith DE, Chalmers JD, et al. Development of Drugs for Nontuberculous Mycobacterial Disease: Clinicians' Interpretation of a US Food and Drug Administration Workshop. *Chest*. Feb 2021;159(2):537-543. doi:10.1016/j.chest.2020.08.2055
14. Castillo M, Freire E, Romero VI. Primary ciliary dyskinesia diagnosis and management and its implications in America: a mini review. *Front Pediatr*. 2023;11:1091173. doi:10.3389/fped.2023.1091173
15. Marshall JE, Mercaldo RA, Lipner EM, Prevots DR. Incidence of nontuberculous mycobacteria infections among persons with cystic fibrosis in the United States (2010-2019). *BMC Infect Dis*. Jul 24 2023;23(1):489. doi:10.1186/s12879-023-08468-6

16. Kim Y, Yoon JH, Ryu J, et al. Gastroesophageal Reflux Disease Increases Susceptibility to Nontuberculous Mycobacterial Pulmonary Disease. *Chest*. Feb 2023;163(2):270-280. doi:10.1016/j.chest.2022.08.2228
17. Loebinger MR, Quint JK, van der Laan R, et al. Risk Factors for Nontuberculous Mycobacterial Pulmonary Disease: A Systematic Literature Review and Meta-Analysis. *Chest*. Nov 2023;164(5):1115-1124. doi:10.1016/j.chest.2023.06.014
18. Biciusca T, Zielbauer AS, Anton T, et al. Differential radiological features of patients infected or colonised with slow-growing non-tuberculous mycobacteria. *Sci Rep*. Jun 10 2024;14(1):13295. doi:10.1038/s41598-024-64029-0
19. Hamao N, Ito I, Oi I, et al. Clinical phenotypes of nontuberculous mycobacterial disease by cluster analysis based on pulmonary function. *Respir Med*. Apr-May 2024;225:107600. doi:10.1016/j.rmed.2024.107600
20. Huang HL, Lee MR, Liu CJ, et al. Predictors of radiographic progression for NTM-pulmonary disease diagnosed by bronchoscopy. *Respir Med*. Jan 2020;161:105847. doi:10.1016/j.rmed.2019.105847
21. Garcia B, Wilmskoetter J, Grady A, Mingora C, Dorman S, Flume P. Chest Computed Tomography Features of Nontuberculous Mycobacterial Pulmonary Disease Versus Asymptomatic Colonization: A Cross-sectional Cohort Study. *J Thorac Imaging*. May 1 2022;37(3):140-145. doi:10.1097/RTI.0000000000000610
22. Kim JS, Tanaka N, Newell JD, et al. Nontuberculous mycobacterial infection: CT scan findings, genotype, and treatment responsiveness. *Chest*. Dec 2005;128(6):3863-9. doi:10.1378/chest.128.6.3863
23. Mirsaeidi M, Hadid W, Ericsson B, Rodgers D, Sadikot RT. Non-tuberculous mycobacterial disease is common in patients with non-cystic fibrosis bronchiectasis. *Int J Infect Dis*. Nov 2013;17(11):e1000-4. doi:10.1016/j.ijid.2013.03.018
24. Lee G, Lee KS, Moon JW, et al. Nodular bronchiectatic Mycobacterium avium complex pulmonary disease. Natural course on serial computed tomographic scans. *Ann Am Thorac Soc*. Aug 2013;10(4):299-306. doi:10.1513/AnnalsATS.201303-062OC
25. Diel R, Lipman M, Hoefsloot W. High mortality in patients with Mycobacterium avium complex lung disease: a systematic review. *BMC Infect Dis*. May 3 2018;18(1):206. doi:10.1186/s12879-018-3113-x
26. Chae G, Park YE, Chong YP, Lee HJ, Shim TS, Jo KW. Treatment Outcomes of Cavitory Nodular Bronchiectatic-Type Mycobacterium avium Complex Pulmonary Disease. *Antimicrob Agents Chemother*. Sep 20 2022;66(9):e0226121. doi:10.1128/aac.02261-21
27. Koh WJ, Moon SM, Kim SY, et al. Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. *Eur Respir J*. Sep 2017;50(3)doi:10.1183/13993003.02503-2016
28. Reiff DB, Wells AU, Carr DH, Cole PJ, Hansell DM. CT findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types. *AJR Am J Roentgenol*. Aug 1995;165(2):261-7. doi:10.2214/ajr.165.2.7618537
29. Ku JH, Ranches G, Siegel SAR, Winthrop KL. 'Lady Windermere's counterpart? Pulmonary nontuberculous mycobacteria in men with bronchiectasis. *Diagn Microbiol Infect Dis*. Feb 2020;96(2):114916. doi:10.1016/j.diagmicrobio.2019.114916

30. Han MK, Zhou Y, Murray S, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. *Lancet Respir Med*. Jul 2014;2(7):548-56. doi:10.1016/S2213-2600(14)70069-4
31. Richardson H, Dicker AJ, Barclay H, Chalmers JD. The microbiome in bronchiectasis. *Eur Respir Rev*. Sep 30 2019;28(153)doi:10.1183/16000617.0048-2019
32. Sulaiman I, Wu BG, Chung M, et al. Lower Airway Dysbiosis Augments Lung Inflammatory Injury in Mild-to-Moderate Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med*. Nov 15 2023;208(10):1101-1114. doi:10.1164/rccm.202210-1865OC
33. Li R, Li J, Zhou X. Lung microbiome: new insights into the pathogenesis of respiratory diseases. *Signal Transduct Target Ther*. Jan 17 2024;9(1):19. doi:10.1038/s41392-023-01722-y
34. Garate-Carrillo A, Gonzalez J, Ceballos G, Ramirez-Sanchez I, Villarreal F. Sex related differences in the pathogenesis of organ fibrosis. *Transl Res*. Aug 2020;222:41-55. doi:10.1016/j.trsl.2020.03.008

Table 1. Cohort Demographics

Demographics (N = 181)	
Sex (Females, %)	129 (71.3%)
Age (years)	71 (64 -78.5)
Ethnicity	
White	155 (85.6%)
African American	14 (8%)
Asian	4 (2%)
Other	8 (4.4%)
BMI (kg/m ²)	21.45 (18.88-25.97)
Pulmonary outcomes	
FEV ₁ (% predicted)	71 (53 – 91.25)
PA/a ratio	0.75 (0.68-0.86)
PA/a ratio > 1	13 (7.1%)
Reiff's score	5 (3-7)
Cavitary disease	41 (22.7%)
History of smoking	77 (42.5%)
Symptomatic disease	146 (80.7%)
Comorbidities (N = 122)	
Emphysema	31 (17%)
COPD	31 (17%)
Lung cancer	9 (4.9%)
Other malignancies	20 (11%)
Immunocompromised	24 (13.2%)
GERD	69 (38.1%)
ILD	7 (3.9%)
SLE	1 (0.6%)
Other	19 (10.5%)
Multiple comorbidities	56 (30.9%)
Microbiology	
<i>M. Avium complex</i>	140 (77.3%)
<i>M. Abscessus</i>	8 (4.4%)
<i>M. Gordonae</i>	4 (2.2%)
<i>M. Kansasii</i>	3 (1.7%)
<i>M. Chelonae</i>	2 (1.1%)
Multiple NTM	12 (6.6%)
Other NTM	12 (6.6%)
Co-infection with other microorganisms:	59 (32.6%)
<i>P. aeruginosa</i>	22 (37.3%)
<i>H. influenzae</i>	4 (6.8%)
<i>S. maltophilia</i>	5 (8.5%)
<i>S. aureus</i>	4 (6.8%)
Other bacteria	9 (15.3%)
Fungal	8 (13.6%)
Polymicrobial	7(11.9%)
Treatment	

Current on treatment	97 (53.6%)	Data are presented as median and interquartile range or number and proportion.
Less than 1 year	35 (36.1%)	
More than 1 year	62 (63.9%)	
Reason for off-treatment		
Culture conversion	23 (53.5%)	
Antimicrobial side effects	9 (20.9%)	
Completed 18 months without conversion	9 (20.9%)	
Deceased	1 (2.3%)	
Lost to follow-up	1 (2.3%)	
Refractory infection	62 (34.3%)	
Recurrent infection	17 (9.4%)	

Abbreviations: BMI – Body Mass Index; FEV₁ – Forced Expiratory Volume in 1 minute; PA/a ratio – Pulmonary artery/aorta ratio; COPD – Chronic Obstructive Pulmonary Disease; GERD – Gastroesophageal reflux disease; ILD – Interstitial Lung Disease; SLE – Systemic Lupus Erythematosus; NTM – Non Tuberculous Mycobacteria.

Table 2. Demographics By Sex

	Female (N=129)	Male (N=52)	p-value
Age (years)	71 (64-78.5)	68 (61.3-78.8)	0.561
Ethnicity			
White	111 (86.1%)	44 (84.6%)	0.081
African American	7 (5.4%)	7 (13.5%)	
Asian	4 (3.1%)	0 (0%)	
Other	7 (5.4%)	1 (1.9%)	
BMI (kg/m ²)	20.9 (18.9-25.6)	23.3 (19.6-27.8)	0.119
Symptomatic disease	105 (81.4%)	41 (78.6%)	0.696
Current on treatment	62 (48.1%)	35 (67.3%)	0.03
Less than 1 year	20 (15.5%)	15 (28.8%)	0.102
More than 1 year	42 (32.6%)	20 (38.5%)	
Reason for off-treatment			
Culture conversion	23 (60.5%)	0 (0%)	0.04
Antimicrobial side effects	7 (18.4%)	2 (40%)	
Completed 18 months without conversion	6 (15.8%)	3 (60%)	
Deceased	1 (2.6%)	0 (0%)	
Lost to follow-up	1 (2.6%)	0 (0%)	0.867
Refractory infection	45 (34.9%)	17 (32.7%)	
Recurrent infection	11 (8.5%)	6 (11.5%)	0.143
FEV ₁ (% predicted)	74 (53-93)	67 (46-81)	0.071
PA/a ratio	0.73 (0.68-0.82)	0.75 (0.68-0.86)	0.703
PA/a ratio > 1	9 (7%)	4 (7.7%)	0.815
History of smoking	43 (34.1%)	38 (65.4%)	0.0001
Emphysema	11 (8.53%)	20 (38.5%)	< 0.0001
COPD	15 (11.6%)	16 (30.8%)	0.002
Lung cancer	5 (3.9%)	4 (7.7%)	0.304
Other malignancies	14 (10.9%)	6 (11.5%)	0.894
Immunocompromised	19 (14.7%)	5 (9.6%)	0.346
GERD	52 (40.3%)	17 (32.7%)	0.337
ILD	5 (3.9%)	2 (3.9%)	0.992
SLE	1 (0.8%)	0 (0%)	0.41
Other	16 (12.4%)	3 (5.8%)	0.165
Multiple comorbidities	34 (26.4%)	22 (42.3%)	0.03
Scoliosis	37 (28.7%)	13 (25%)	0.614
Pectus excavatum	3 (2.3%)	1 (1.92%)	0.866
Hiatal hernia	49 (38%)	13 (25%)	0.09

Data are presented as median and interquartile range or number and proportion. Abbreviations: BMI – Body Mass Index; FEV₁ – Forced Expiratory Volume in 1 minute; PA/a ratio – Pulmonary artery/aorta ratio; COPD – Chronic Obstructive Pulmonary Disease; GERD – Gastroesophageal reflux disease; ILD – Interstitial Lung Disease; SLE – Systemic Lupus Erythematosus. Statistical analysis was performed either with two-tailed Wilcoxon rank sums test or Chi Square test, significance threshold was set at 0.05.

Table 3. Sex-Associated Differences In NTM Infection

	Female	Male	p-value
<i>M. Avium complex</i>	103 (79.8%)	37 (71.2%)	0.012
<i>M. Abscessus</i>	8 (6.2%)	0 (0%)	
<i>M. Gordonae</i>	4 (3.1%)	0 (0%)	
<i>M. Kansaii</i>	1 (0.8%)	2 (3.9%)	
<i>M. Chelonae</i>	1 (0.8%)	1 (1.9%)	
Multiple NTM	5 (3.9%)	7 (13.5%)	0.615
Other NTM	7 (5.4%)	5 (9.6%)	
Co-infection with other microorganisms:	45 (36%)	15 (31.9%)	
<i>P. aeruginosa</i>	15 (33.3%)	7 (50%)	0.214
<i>H. influenzae</i>	2 (4.4%)	2 (14.3%)	
<i>S. maltophilia</i>	3 (6.7%)	2 (14.3%)	
<i>S. aureus</i>	3 (6.7%)	1 (7.1%)	
Other bacteria	8 (17.8%)	1 (7.1%)	
Fungal	8 (17.8%)	0 (0%)	
Polymicrobial	6 (13.4%)	1 (7.1%)	

Data are presented as number of individuals and proportion. Statistical analysis was performed with Chi Square test, significance threshold was set at 0.05. NTM – nontuberculous mycobacterium.

Table 4. Radiographic sex-associated differences in NTM pulmonary disease.

	All (N =181)	Female (N=129)	Male (N=52)	p-value
Whole lung				
Reiff's score	5 (3-7)	5 (3-7)	6 (3-7)	0.632
Cavitary	41 (22.7%)	21 (16.3%)	20 (38.5%)	0.001
Tree-in-bud	145 (80.1%)	107 (83%)	38 (73.1%)	0.141
Fibrosis	81 (44.8%)	63 (48.8%)	18 (34.6%)	0.08
Atelectasis	76 (42%)	57 (44.2%)	19 (36.5%)	0.343
Nodules	165 (91.2%)	120 (93%)	45 (86.5%)	0.18
Lobectomy	5 (2.8%)	3 (2.3%)	2 (3.9%)	0.584
Ground glass opacity	46 (25.4%)	33 (25.6%)	13 (25%)	0.935
Consolidation	16 (8.8%)	11 (8.5%)	5 (9.6%)	0.817
Right upper lobe				
Reiff's score	1 (1-1)	1 (1-1)	1 (1-1)	0.04
Cavitary	21 (11.6%)	11 (8.5%)	10 (19.2%)	0.04
Tree-in-bud	86 (47.5%)	62 (48.1%)	24 (46.2%)	0.816
Fibrosis	74 (40.9%)	59 (45.7%)	15 (28.8%)	0.03
Atelectasis	13 (7.2%)	9 (7%)	4 (7.7%)	0.867
Nodules	110 (60.8%)	77 (59.7%)	33 (63.5%)	0.637
Lobectomy	1 (0.6%)	1 (0.8%)	0 (0%)	0.41
Ground glass opacity	23 (12.7%)	17 (13.2%)	6 (11.5%)	0.763
Consolidation	4 (2.2%)	3 (2.3%)	1 (1.9%)	0.866
Left upper lobe				
Reiff's score	1 (0-1)	1 (0-1)	1 (0-1)	0.002
Cavitary	14 (7.7%)	4 (3.1%)	10 (19.2%)	0.0002
Tree-in-bud	66 (36.5%)	49 (38%)	17 (32.7%)	0.501
Fibrosis	68 (37.6%)	55 (42.6%)	13 (25%)	0.02
Atelectasis	9 (5%)	5 (3.9%)	4 (7.7%)	0.304
Nodules	97 (53.6%)	72 (55.8%)	25 (48.1%)	0.345
Lobectomy	2 (1.1%)	0 (0%)	2 (3.9%)	0.02
Ground glass opacity	20 (11.1%)	15 (11.6%)	5 (9.6%)	0.692
Consolidation	3 (1.7%)	2 (1.6%)	1 (1.9%)	0.861
Right lower lobe				
Reiff's score	1 (0-1)	1 (0-1)	1 (0-1)	0.845
Cavitary	7 (3.9%)	5 (3.9%)	2 (3.9%)	0.993
Tree-in-bud	101 (55.8%)	79 (61.2%)	22 (42.3%)	0.02
Fibrosis	11 (6.1%)	6 (4.7%)	5 (9.6%)	0.224
Atelectasis	17 (9.4%)	10 (7.8%)	7 (13.6%)	0.248

Nodules	109 (60.2%)	86 (66.7%)	23 (44.2%)	0.005
Lobectomy	0 (0%)	0 (0%)	0 (0%)	NA
Ground glass opacity	23 (12.7%)	16 (12.4%)	7 (13.5%)	0.847
Consolidation	6 (3.3%)	4 (3.1%)	2 (3.9%)	0.803
Left lower lobe				
Reiff's score	1 (0-1)	1 (0-1)	1 (0-1)	0.12
Cavitary	7 (3.9%)	5 (3.9%)	2 (3.9%)	0.993
Tree-in-bud	76 (42%)	55 (42.6%)	21 (40.4%)	0.781
Fibrosis	11 (6.1%)	6 (4.7%)	5 (9.6%)	0.224
Atelectasis	23 (12.7%)	18 (14%)	5 (9.6%)	0.417
Nodules	89 (49.2%)	65 (50.4%)	24 (46.2%)	0.606
Lobectomy	0 (0%)	0 (0%)	0 (0%)	NA
Ground glass opacity	19 (10.5)	15 (11.6%)	4 (7.7%)	0.422
Consolidation	5 (2.8%)	4 (3.1%)	1 (1.9%)	0.651
Right middle lobe				
Reiff's score	1 (1-1)	1 (1-2)	1 (0-1)	0.003
Cavitary	2 (1.1%)	1 (0.8%)	1 (1.9%)	0.528
Tree-in-bud	92 (50.8%)	71 (55.5%)	21 (40.4%)	0.066
Fibrosis	10 (5.5%)	5 (3.9%)	5 (9.6%)	0.148
Atelectasis	31 (17.1%)	27 (20.9%)	4 (7.7%)	0.02
Nodules	105 (58%)	81 (63.3%)	24 (46.2%)	0.03
Lobectomy	2 (1.1%)	2 (1.6%)	0 (0%)	0.241
Ground glass opacity	22 (12.2%)	17 (13.3%)	5 (9.6%)	0.487
Consolidation	6 (3.3%)	5 (3.9%)	1 (1.9%)	0.479
Lingula				
Reiff's score	1 (0-1)	1 (0-1)	0 (0-1)	0.119
Cavitary	2 (1.1%)	2 (1.6%)	0 (0%)	0.243
Tree-in-bud	70 (38.7%)	54 (41.9%)	16 (30.8%)	0.162
Fibrosis	14 (7.7%)	9 (7%)	5 (9.6%)	0.555
Atelectasis	26 (14.4%)	21 (16.3%)	5 (9.6%)	0.232
Nodules	81 (44.8%)	62 (48.1%)	19 (36.5%)	0.156
Lobectomy	2 (1.1%)	1 (0.8%)	1 (1.9%)	0.525
Ground glass opacity	13 (7.2%)	7 (5.4%)	6 (11.5%)	0.167
Consolidation	4 (2.2%)	3 (2.3%)	1 (1.9%)	0.866

Data are presented as median and interquartile range or number and proportion. Statistical analysis was performed with Chi Square test, significance threshold was set at 0.05. NA – not applicable.